Learn More
BACKGROUND Myxomatous mitral valve disease (MMVD) continues to be an important cause of morbidity and mortality in geriatric dogs despite conventional therapy. HYPOTHESIS Pimobendan in addition to conventional therapy will extend time to sudden cardiac death, euthanasia for cardiac reasons, or treatment failure when compared with conventional therapy plus(More)
BACKGROUND The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported. HYPOTHESIS That chronic oral administration of pimobendan to Dobermans with preclinical DCM will delay the onset of CHF or sudden death and improve survival. ANIMALS Seventy-six client-owned Dobermans recruited at 10(More)
BACKGROUND Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. HYPOTHESIS/OBJECTIVES Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not(More)
The purpose of this investigation was to determine if stabilization of the nontested lower extremity influences the peak torque generated by the knee musculature of the opposite extremity during isokinetic testing. The subjects included 15 males and 15 females, between 18 to 30 years of age, who had no history of right knee pain or pathology. A Cybex I(More)
  • 1